Abstract
Twenty-five schizophrenic outpatient subjects in a depot neuroleptic discontinuation study received an amphetamine challenge approximately 6 weeks after their last dose. Only five of these showed greater than three-point increases in positive symptoms on the BPRS, and all five relapsed within 30 days of the challenge. The 20 with less than three-point increases in positive symptoms showed extremely variable stability, relapsing from 20–>600 days after the challenge. Thus, increase in positive symptoms after amphetamine may identify a group at risk for rapid relapse after neuroleptic discontinuation, but lack of such a response gives little prognostic information.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology 72:17–19
Angrist B, Peselow E, Rotrosen J, Gershon S (1981) Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. In: Angrist B et al. (eds) Recent advances in neuropsychopharmacology. Pergamon, Oxford New York (Advances in the biosciences, vol 31, pp 49–54)
Angrist B, Peselow E, Robenstein M, Corwin J, Rotrosen J (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychoparmacology 78:128–130
Baldessarini RJ, Tarsy D (1978) Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A generation of progress, Raven, New York, pp 993–1004
Brown WA, Laughren T (1981) Low serum prolactin and early relapse following neuroleptic withdrawal. Am J Psychiatry 138:237–239
Crow TJ (1980) Molecular pathology in schizophrenia: More than one disease process? Br Med J 280:66–68
Delay J (1947) Pharmacological exploration of the personality: Narcoanalysis and methadrine shock. Proc R Soc Med 42:491–496
Guttman E, Sargant W (1937) Observations on benzedrine. Br Med J 1:1013–1015
Guy W (1976) ECDEU Assessment manual for psychopathology. US Department of Health, Education and Welfare, Washington, DC
Hope JM, Callaway E, Sands L (1951) Intravenous pervitan and the psychopathology of schizophrenia. Dis Nerv Syst 12:67–72
Janowsky DS, El-Yousef K, Davis JM, Sekerke J (1973) Provocation of schizophrenic symptoms by intravenous methylphenidate. Arch Gen Psychiatry 28:185–191
Langer G, Sachar ES, Halper FS, Gruen PH, Solomen M (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 45:996–1002
Lieberman J, Kane J, Gadaletta D, Brenner R, Lesser M, Kinon B (1984) Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 141:633–638
Mattson RH, Calverly JR (1968) Dextroamphetamine sulfate-induced dyskinesias. JAMA 204:400–402
Merali Z (1981) Prolactin levels and amphetamine-induced behavioral changes following fluphenazine decanoate administration. In: Radouco-Thomas C, Garcin F (eds) Prog neuropsychopharmacol vol 5. Pergamon, Oxford New York, pp 603–607
Meyerson A (1936) Effect of benzedrine sulfate on mood and fatigue in normal and neurotic persons. Arch Neurol Psychiatry 36:816–822
Prinzmetal M, Bloomberg W (1935) The use of benzedrine for the treatment of narcolepsy. JAMA 105:2051–2054
Sargant W, Slater E (1954) An introduction to physical methods of treatment in psychiatry. Williams and Wilkins, Baltimore p 169
Schube PG, McManamy MC, Trapp CE, Meyerson A (1937) The effect of benzedrine sulfate on certain abnormal mental states. Am J Psychiatry 94:27–32
Van Kammen DP, Docherty JP, Bunney WE Jr (1982a) Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 17:233–242
Van Kammen DP, Bunney WE, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN (1982b) d-Amphetamine-induced heterogenous changes in psychotic behavior in schizophrenia. Am J Psychiatry 139:991–997
Wistedt B, Wiles D, Kolakowska T (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1:1163
Wooley LF (1938) The clinical effect of benzedrine sulfate in mental patients with retarded activity. Psychiatr Q 12:66–83
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Angrist, B., Peselov, E., Rubinstein, M. et al. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85, 277–283 (1985). https://doi.org/10.1007/BF00428187
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00428187